Literature DB >> 18623123

Comparison between a liquid chromatography-tandem mass spectrometry assay and a fluorescent polarization immunoassay to measure whole blood everolimus concentration in heart and renal transplantations.

Eric Dailly1, G Deslandes, M Hourmant, T Petit, C Renaud, M Treilhaud, P Jolliet.   

Abstract

Various methods [fluorescent polarization immunoassay (FPIA) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay] are used for therapeutic drug monitoring of everolimus. The aim of this study is to compare these assays in renal and heart transplantation. The correlation between results was investigated by linear regression in 44 patients (24 heart recipients and 20 renal recipients--137 samples). The comparison between assays was performed by a paired t-test. A highly significant correlation was found between FPIA and LC-MS/MS in heart and renal recipients [FPIA=0.851 x LC-MS/MS+1.773r(2)=0.8738 (P<0.001)]. Paired t-tests did not show a significant difference between everolimus whole blood concentrations in the populations of heart and renal recipients or heart recipients or renal recipients. FPIA and LC-MS/MS assays gave consistent overall results although some significant differences were observed in some samples between these methods indicating that FPIA assay has limitations that deserve further investigations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18623123      PMCID: PMC6649002          DOI: 10.1002/jcla.20258

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  9 in total

Review 1.  The role of therapeutic drug monitoring in individualizing immunosuppressive drug therapy: recent developments.

Authors:  Michael Oellerich; Victor W Armstrong
Journal:  Ther Drug Monit       Date:  2006-12       Impact factor: 3.681

2.  Comparison of the Innofluor certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation.

Authors:  Sara Baldelli; Alberto Crippa; Roberta Gabrieli; Roberto Fiocchi; Norberto Perico; Simona Merlini; Cosimo Ottomano; Dario Cattaneo
Journal:  Clin Biochem       Date:  2006-09-14       Impact factor: 3.281

3.  Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation.

Authors:  GholamAli Khoschsorur; Franz Fruehwirth; Sieglinde Zelzer; Mariana Stettin; Gabriele Halwachs-Baumann
Journal:  Clin Chim Acta       Date:  2007-01-25       Impact factor: 3.786

4.  Internal standard selection for immunosuppressant drugs measured by high-performance liquid chromatography tandem mass spectrometry.

Authors:  Paul J Taylor
Journal:  Ther Drug Monit       Date:  2007-02       Impact factor: 3.681

5.  Evaluation of a fluorescent polarization immunoassay for whole blood everolimus determination using samples from renal transplant recipients.

Authors:  Paul Salm; Christopher Warnholtz; Jared Boyd; Lili Arabshahi; Peter Marbach; Paul J Taylor
Journal:  Clin Biochem       Date:  2006-04-21       Impact factor: 3.281

6.  Internal standard selection for the high-performance liquid chromatography tandem mass spectroscopy assay of everolimus in blood.

Authors:  Karin Hoogtanders; Jaques van der Heijden; Leo Ml Stolk; Cees Neef; Maarten Christiaans; Johannes van Hooff
Journal:  Ther Drug Monit       Date:  2007-10       Impact factor: 3.681

Review 7.  Everolimus: a review of its use in renal and cardiac transplantation.

Authors:  Christopher Dunn; Katherine F Croom
Journal:  Drugs       Date:  2006       Impact factor: 9.546

8.  Simultaneous determination of four immunosuppressants by means of high speed and robust on-line solid phase extraction-high performance liquid chromatography-tandem mass spectrometry.

Authors:  Therese Koal; Michael Deters; Bruno Casetta; Volkhard Kaever
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-06-15       Impact factor: 3.205

9.  Crossreactivity of isolated everolimus metabolites with the Innofluor Certican immunoassay for therapeutic drug monitoring of everolimus.

Authors:  Tobin Strom; Manuel Haschke; Jared Boyd; Mark Roberts; Lili Arabshahi; Peter Marbach; Uwe Christians
Journal:  Ther Drug Monit       Date:  2007-12       Impact factor: 3.681

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.